very good reality check

I could not agree more with post 'stmccallum' from across the street.

He is dead on IMO on several accounts:

1) Wolgen's compensation is too high given the cash problem (that poster checked various other CEO comparative compensations in the industry and someone else did so on this forum as well).

2) 'stmccallum' also does a great job of rebutting Wolgen's video comments about how 'quickly' they have gotten the drug submitted.

Melanotan goes back to around 1990! This management team had the advantage of Epitan's past trials! This drug has been in various studies for 20 years!

Thanks to 'stmccallum' for saying exactly what I was thinking.

And by the way, they were supposed to have an FDA meeting about EPP direction late last year. Whatever happened to that? They still have to meet with them.